# PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
Canonical URL: https://biopharmsignal.com/news/PRTC/puretech-founded-entity-seaport-therapeutics-reports-positive-multiple-ascending-dose-data-from-phase-1-proof-of-concept-trial-of-glyphagotm-in-healthy-volunteers
Ticker: PRTC
Company: PureTech Health
Source: PureTech Health
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.puretechhealth.com
## Summary

RNS Number: 5025H PureTech Health PLC 09 June 2026 9 June 2026 PureTech Health plc PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers PureTech Health plc (LSE: PRTC) (" PureTech "

## Article Body
RNS Number: 5025H PureTech Health PLC 09 June 2026 9 June 2026 PureTech Health plc PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers PureTech Health plc (LSE: PRTC) (" PureTech "
## Recent Company News
- 2026-07-02 06:01 EST — [PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)](https://biopharmsignal.com/news/PRTC/puretech-founded-entity-celea-therapeutics-completes-180-million-financing-to-ad-3954c132) — Source: PureTech Health
- 2026-07-02 06:00 EST — [PureTech Announces Completion of $180 Million Financing for Founded Entity Celea Therapeutics to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)](https://biopharmsignal.com/news/PRTC/puretech-announces-completion-of-180-million-financing-for-founded-entity-celea--b2099580) — Source: PureTech Health
- 2026-06-25 13:46 EST — [Results of Annual General Meeting](https://biopharmsignal.com/news/PRTC/results-of-annual-general-meeting) — Source: PureTech Health
- 2026-06-25 13:46 EST — [PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers](https://biopharmsignal.com/news/PRTC/puretech-founded-entity-seaport-therapeutics-reports-positive-multiple-ascending-dose-data-from-phase-1-proof-of-concept-trial-of-glyphagotm-in-healthy-volunteers) — Source: PureTech Health
- 2026-06-25 13:46 EST — [PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference](https://biopharmsignal.com/news/PRTC/puretech-to-showcase-deupirfenidone-program-at-the-american-thoracic-society-international-conference) — Source: PureTech Health
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)